Association of CYP2J2 polymorphism with susceptibility to psoriasis in Turkish population: a case–control study

Hayran, Yıldız; Allı, Nuran; Uysal, Pınar; Çandar, Tuba

doi:10.1016/j.abd.2019.04.006

Cited by 1 publication

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytochrome P450 (CYP) is a multi-gene superfamily of constitutive and inducible heme-containing monooxygenases, involved in the metabolism of various xenobiotics and endogenous substrates ( Blake et al, 2013 ; Wang et al, 2017 ; Dutkiewicz and Mikstacka, 2018 ). The CYP enzyme (P450) is located in the mitochondria and endoplasmic reticulum ( Hayran et al, 2020 ). These enzymes use molecular oxygen and equivalent electrons transferred from the NADPH-P450 reductase in the endoplasmic reticulum or the ferredoxin and ferredoxin reductase in the mitochondria to catalyze the monooxygenase reaction ( Renaud et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Enzyme-Responsive Materials as Carriers for Improving Photodynamic Therapy

et al. 2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a mini-invasive therapy on malignancies via reactive oxygen species (ROS) induced by photosenitizer (PS) upon light irradiation. However, poor target of PS to tumor limits the clinical application of PDT. Compared with normal tissues, tumor tissues have a unique enzymatic environment. The unique enzymatic environment in tumor tissues has been widely used as a target for developing smart materials to improve the targetability of drugs to tumor. Enzyme-responsive materials (ERM) as a smart material can respond to the enzymes in tumor tissues to specifically deliver drugs. In PDT, ERM was designed to react with the enzymes highly expressed in tumor tissues to deliver PS in the target site to prevent therapeutic effects and avoid its side-effects. In the present paper, we will review the application of ERM in PDT and discuss the challenges of ERM as carriers to deliver PS for further boosting the development of PDT in the management of malignancies.

show abstract